Posted on

Blackhawk’s MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial

Blackhawk’s MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial

  • Successful completion of Phase 1 Clinical Trials 
  • MindBio remains the only organization in the world to have successfully obtained government approvals for a doctor to prescribe LSD (lysergic acid diethylamide) to patients to take the drug unsupervised in the community in the same way they would take any other medicine 
  • Phase 1 clinical trial report and safety data is being analyzed and will be announced shortly 
  • Phase 2 clinical trials currently in development 
  • MindBio spin-out plans progressing as scheduled 

Vancouver, British Columbia – TheNewswire – May 3rd, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) has completed its 12 month Phase 1 clinical trial microdosing LSD in 80 healthy participants.

MindBio is developing a microdosing regimen using LSD to treat mental health disorders such as depression.  To get these novel treatments to market, MindBio needs to prove safety and efficacy of the treatment using a rigorous clinical trial process.

The Phase 1 Clinical Trial is the largest safety study of its kind that has ever been completed under a randomized, double blind placebo controlled discipline, the results of which will support development of MindBio’s intellectual property and progression towards commercialization of treatments for mental health conditions.

MindBio is looking forward to analyzing the data from the Phase 1 clinical trial to further inform its planned Phase 2 clinical trials.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system.  In larger doses, LSD is a hallucinogenic drug that substantially changes cognition, thinking, mood and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.  

MindBio is working towards becoming the first to market by commercializing a microdosing regimen with substantial potential global mental health care benefits.

“We are proud of the incredible work of our scientific team and the completion of this great milestone as we head towards developing game-changing treatments for mental health conditions,” said Frederick Pels, CEO of Blackhawk.

MindBio is continuing to progress towards its previously announced spin out which it anticipates completing following receipt of all necessary approvals including approval by the shareholders of Blackhawk.  The spin out of MindBio is expected to create significant shareholder value as each Blackhawk shareholder will receive shares in MindBio upon completion of the spin out.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics, Digital Mind Therapeutics, Blum Distributors Ltd as well as an equity position in Gaia Grow Corp (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawks Mindbio Therapeutics Announces Investment in Health Research Platform Quantified Citizen, a Health Technology Company Disrupting and Decentralizing Clinical Research

Blackhawks Mindbio Therapeutics Announces Investment in Health Research Platform Quantified Citizen, a Health Technology Company Disrupting and Decentralizing Clinical Research

Vancouver, British Columbia – TheNewswire – March 15, 2022 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) has co-invested in Quantified Citizen’s (quantifiedcitizen.com) latest funding round with other notable investors around the world. The investment was funded from MindBio existing working capital.

Quantified Citizen is a leading mobile health research platform with over 52,000 users and over 17,000 participants in their global microdosing study, which was published in the prestigious science journal Nature Scientific Reports.

MindBio is in the final completion stages of a world first Phase 1 clinical trial microdosing LSD to patients at home. Co-founder of MindBio, Justin Hanka said “We are impressed with the extensive work that Quantified Citizen is doing in decentralized clinical trials and we are excited to invest and participate in their journey and to explore synergies in our respective microdosing clinical trials.  Data is the key to developing safe and effective treatment strategies and understanding the nuances of the effects of psychedelic medicines on patient health”.

Quantified Citizen has created an innovative health technology platform that seeks to democratize scientific discovery through digitized health measures and a community of professional researchers and passionate citizen scientists. “We envision a world where doing scientifically valid health research is as fast and easy as creating a website, with the same global reach. Where scientific tinkering and self-examination are normalized, vastly accelerating the pace of discovery by unlocking unexamined data,” shares co-founder and CEO Eesmyal Santos-Brault.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system with the aim of changing the course of mental health.  

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods Co., MindBio Therapeutics, Digital Mind Technologies as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk’s MindBio Therapeutics Announces Platinum Sponsorship of Plant Medicine Week in Malta

Blackhawk’s MindBio Therapeutics Announces Platinum Sponsorship of Plant Medicine Week in Malta

Co-Founder Justin Hanka to Deliver Keynote Address

Provides Video Update After Microdose Molecular Masterclass

Vancouver, British Columbia – TheNewswire – March 08, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) is a key note presentor and major supporter of Plant Medicine Week in Malta.

Plant Medicine Week (plantmedicineweek.com) is being held in Valletta, Malta in April (5th – 8th) to share diverse and inspiring perspectives of the latest advances from the medical cannabis and psychedelics industries through case studies, presentations, Q&A and exhibition.

Co-founder of MindBio Therapeutics, Justin Hanka, will be sharing his perspectives on clinical trials, drug development and his views on the responsibility to change the course of mental health and the importance of investment in the sector.  Recently Mr Hanka participated in Microdose Psychedelic Insights molecular masterclass on LSD (lysergic acid diethylamide) which can be viewed on Youtube here.  

MindBio Therapeutics is in the completion stages of a world first clinical trial in 80 patients who are microdosing LSD at home.  The Clinical Trial’s Independent Review Board and Safety Monitoring Committee recently found no adverse events in the Phase 1 clinical trial and approved it’s continuation, with almost 12 months of testing now complete.   MindBio is now preparing for its continuation study, a Phase 2 clinical trial microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial microdosing LSD in late stage cancer patients experiencing existential distress, depression and anxiety.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system with the aim of changing the course of mental health.  

“We are excited to support Plant Medicine Week in Malta and showcase our clinical trials microdosing psychedelic medicines as MindBio prepares for its upcoming spin-out listing on the Canadian Securities Exchange” said Frederick Pels, CEO of Blackhawk.

Plant Medicine Week.  More information and tickets available here.

Microdose Molecular Masterclass video by MindBio Co-Founder Justin Hanka can be viewed on Youtube here.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods Co., MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Publishes MindBio Therapeutics Investor Presentation & Q&A Event on Website

Blackhawk Publishes MindBio Therapeutics Investor Presentation & Q&A Event on Website

Vancouver, British Columbia – TheNewswire – February 3, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that it has published its recent investor presentation and Q&A event on their website here: https://www.blackhawkgrowth.com/investors/media.html

The presentation event, held on Feburary 2nd, 2022, was a huge success with large groups of both retail and institutional investors from Australia and Canada dialing into the video conference call.

The presentation and Q&A session can also be seen here: https://vimeo.com/manage/videos/672968969

“This was a great opportunity for investors to meet Justin Hanka and get a better understanding of MindBio and its value-add for our shareholders” said Frederick Pels, CEO of Blackhawk Growth Corp. “The presentation gave us an opportunity to share information on the world class clinical trials and also for shareholders to ask questions relating to the spinout and listing of MindBio. We look forward to keeping our shareholders updated with our progress over the coming months.”

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology, as well as an equity position in Gaia Grow (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk’s MindBio Therapeutics Ahead of Schedule to Complete Phase 1 Clinical Trial Microdosing of Psychedelic Medicines and Provides Updates on Spinout Process

Blackhawk’s MindBio Therapeutics Ahead of Schedule to Complete Phase 1 Clinical Trial Microdosing of Psychedelic Medicines and Provides Updates on Spinout Process

Vancouver, British Columbia – TheNewswire – January 24, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary MindBio Therapeutics Pty Ltd. (“MindBio”) has entered into the final stage of a Phase 1 clinical trial involving microdosing LSD and is on track for completion in March 2022, ahead of its original 12 month schedule.

At completion of the Phase 1 trial, MindBio will have important data and intellectual property on microdosing of medical psychedelics. Having successfully passed the Phase 1 clinical trial’s independent Data and Safety Monitoring Committee and with no adverse events, MindBio is confident it has sufficient data, protocols and strategy for its next phase of clinical trials.

MindBio has also started preparation work for a Phase 2 clinical trial which includes the design of its proprietary psychedelic microdosing formulations that can subsequently be manufactured under Good Manufacturing Practices (GMP) standards for subsequent use both commercially and in clinical trials.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system.  In larger doses, LSD is a hallucinogenic drug that substantially changes cognition, thinking, mood and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.

MindBio wants to be the first to market by commercializing a microdosing regimen with substantial potential global mental health care benefits that:

  • have potentially lower side effect risk profile to existing pharmacological treatments such as anti-depressants and benzodiazapines for the treatment of a range of mental health conditions; 
  • offer less risk of harm than large, one-off doses of psychedelics; 
  • affect’s brain neuroplasticity after acute administration, in the same way that larger hallucinogenic doses affect the brain, yet the patient is still able to get on with their normal day after ingesting the microdose.  This is not possible with a psychedelic macro-dosing treatment session which requires an in clinic therapeutic session guided by clinicians over many hours; and 
  • is a scalable solution to global mental health treatment. 

The results of this important clinical trial will form the basis for advancing the commercialization of a psychedelic microdosing regimen for safe use in the community.

1. https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity

Update on Spinout Process

Blackhawk is also pleased to report that MindBio is well underway with its proposed spinout.

In December 2021, Blackhawk announced its intention to spinout MindBio as well as Digital Mind Technology, both wholly-owned subsidiaries of Blackhawk, into a newly formed subsidiary of spinco.  It is aniticipated that the spinco will ultimately pursue a separate public listing.

The Company is pleased to report that since the announcement, the Company and its subsidiaries have appointed their legal teams and have progressed with preparation of materials to complete the spinout.

MindBio intends to create a focused multi-disciplinary platform for one of the most progressive psychedelics and mental health development companies in the world with four (4) clinical trials in development and underway this year.  Using novel drug development, microdosing psychedelics, assisted therapies and technology, MindBio is working towards changing the way that mental health disorders are treated.  

It is anticipated that the spin out and listing of MindBio will create significant shareholder value as each Blackhawk shareholder will receive one common share in the newly listed spinco for every share held in Blackhawk, on a pro rata basis, based on a record date that is expected to be set after shareholder and regulatory approvals are received. The Company is expecting to make further announcements on the timetable of the spinout as it becomes available.

“All of our portfolio companies are making significant progress these days”, said Frederick Pels, CEO of Blackhawk. “Our management teams at MindBio and Digital Mind Therapeutics are working hard to complete this Phase 1 clinical trial and move onto its Phase 2, which I am pleased to report is tracking ahead of schedule, bringing us another step closer to commercializing our unique microdosing protocol. In addition, there has been substantial progress on the necessary steps to facilitate our proposed spinout. I look forward to updating shareholders as we progress further.”      

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology, as well as an equity position in Gaia Grow (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please visit us online at www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to of the intended spinout of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk’s MindBio Therapeutics to Develop Psychedelic Medicine in Microdoses Ready for Commercial Use to Treat Major Depressive Disorder

Blackhawk’s MindBio Therapeutics to Develop Psychedelic Medicine in Microdoses Ready for Commercial Use to Treat Major Depressive Disorder

Vancouver, British Columbia – TheNewswire – January 17, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”) is pleased to announce that its wholly-owned subsidiary MindBio Therapeutics Pty Ltd (“MindBio”) is developing a new microdosing formula using LSD (Lysergic Acid Diethylamide) to treat Major Depressive Disorder (“MDD”).  

MindBio aims to develop psychedelic microdosing formulations that can subsequently be manufactured under Good Manufacturing Practices (GMP) standards for subsequent use in both commercially and in Clinical Trials. The principal aim is to develop a LSD microdosing formulation suitable for home use. The feasibility of delivery systems will be confirmed as part of the overall works. The success of the formulations developed will be assessed against standard GMP criteria for dose homogeneity and stability with the aim of a minimum shelf-life of 6 months.

The prevalence of MDD is extraordinarily high and growing. In 2019, the National Institute of Mental Health estimated that 19.4 million people suffered at least one major depressive episode in the United States (www.nimh.nih.gov/health/statistics/major-depression).  MindBio is directly targeting MDD in one of its Phase 2 clinical trials microdosing LSD to create breakthrough treatments for this debilitating mental health condition.  

LSD is a hallucinogenic drug that has a profound impact on cognition, thinking, perception and mood. MindBio is developing a novel medicinal treatment using a microdose formula of LSD.  The benefit of microdoses is the effects of the drug can be sub-perceptual and the patient can conveniently get on with their day immediately after taking the drug without noticing its hallucinogenic effects.  

MindBio recently received feedback from its Phase 1 clinical trial independent Data and Safety Monitoring Committee that the clinical trial is approved to continue after a successful six-month safety review of its use of LSD in healthy participants.  After its positive safety review, MindBio is progressing the development and enhancement of its microdose formulation of LSD in a form for commercial distribution and use.

The new microdose formula will be adapted in the Phase 2 clinical trials and assessed utilizing MindBio’s proprietary technology which will be used to determine an optimal microdose for patients.  

Health Canada Announces Significant Amendment to Special Access Programme

Blackhawk commends Health Canada’s leadership on their recent amendments to the Special Access Programme (SAP), which will now allow physicians to request patient access to psychedelic treatments, including psilocybin-assisted therapy.

The amendments under the SAP came into effect as of January 5, 2022, as published in the Canada Gazette, and allows physicians to request psychedelic treatments on behalf of their patients, on a case-by-case basis, for serious treatment-resistant or life-threatening conditions. This significant amendment has the potential to provide numerous Canadians struggling with serious mental health afflictions with alternative therapies where traditional treatments have failed, or where other treatments are unsuitable or are unavailable in Canada.

Canada’s SAP was designed with the purpose of allowing people access to new, potentially life-saving medications before they are formally approved for routine use in healthcare, however prior to today’s milestone amendment, psychedelic medications have been ineligible for Special Access Programme applications. The regulatory amendment will enable Canadian physicians to apply for psychedelic therapies in a similar process as to how other investigational medications are accessed prior to formal drug approval.

The amendment to SAP by Health Canada is an historic milestone in Canada’s approach to treating mental health conditions and signifies a growing recognition of the important and growing body of research that supports the efficacy of psychedelics and psychedelic-assisted therapies in treating mental health afflictions. According to Health Canada, access to psychedelic treatments will be provided where there is sufficient data to support the safety and efficacy of the targeted drug for a patient’s specific condition.

“This is an important development for MindBio”, said Frederick Pels, CEO of Blackhawk Growth Corp. “Health Canada’s recent amendment to the Special Access Program, has the potential to improve the lives of numerous Canadians suffering from mental health afflictions, including major depression, end-of-life anxiety and even addictions and historical traumas. It also provides doctors and their patients a safe, legal and regulated process for providing alternative treatments to mental health patients that desperately seek alternatives to otherwise failing contemporary modalities.”

Chief Financial Officer Appointment

Zula Kropivnitski has resigned as the Company’s Chief Financial Officer for personal reasons, effectively immediately. The Board of Directors and management would like to thank Ms. Kropivnitski for her contributions to the Company and wish her every success in her future endeavours.

The Company is pleased to announce that Heidi Gutte has been appointed Chief Financial Officer of the Company. Ms. Gutte specializes in providing corporate finance, financial reporting, consulting, taxation and other accounting services to both small businesses as well as public companies in various industries. She also assists in many aspects of clients’ administration, corporate compliance and other activities.

Ms. Gutte earned her bachelor’s degree of computer engineering from the University of Applied Sciences in Brandenburg, Germany. She holds the professional designation of chartered professional accountant (CPA, CGA), and is a member of Chartered Professional Accountants of B.C. and Canada. Ms. Gutte has had extensive experience as a controller and CFO of numerous publicly traded and private corporations in several industries.

About MindBio Therapeutics Pty Ltd. (“MindBio”)

MindBio is a clinical-stage drug development company that is pioneering psychedelic microdosing research and is advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD (posttraumatic stress disorder).

In a world’s first clinical trial of its kind, MindBio is currently conducting Phase 1 clinical trials, that is over 50% complete, at a tier 1 university in a safety study of 80 participants microdosing LSD to patients. The study has received regulatory approval and government funding for the importing of LSD, laboratory work using the drug and approvals for participants to be prescribed the drug; and then patients take the drug at home as they would any other medication. Approvals have also been received for two phase 2 clinical trials involving microdosing LSD in late-stage cancer patients experiencing end-of-life distress.

MindBio is also pioneering the development of microdose formulations and a range of technology and artificial intelligence applications to ensure the safe dosage, use and administration of psychedelic medicines in the community. Early indications show that LSD is tolerated well in microdoses and has a lower side effect profile than the currently prescribed antidepressant drugs. MindBio has a detailed roadmap to conduct further clinical trials, including with other psychedelic substances, and a clear plan to bring newly created intellectual property to market and commercialization.

For more information, please visit https://mindbiotherapeutics.com.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology, as well as an equity position in Gaia Grow (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth Announces Plan to Spin-out Psychedelic Subsidiaries and Proposes 1:1 Distribution Ratio

Blackhawk Growth Announces Plan to Spin-out Psychedelic Subsidiaries and Proposes 1:1 Distribution Ratio

Vancouver, British Columbia – TheNewswire – December 15, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) ( “Blackhawk”), is pleased to announce that it intends to undertake a spin-out transaction whereby the shares of its wholly owned subsidiaries MindBio Therapeutics Pty. Ltd. and Digital Mind Technology Pty Ltd. will form an independent company to focus solely on the psychedelics business. As part of the spin-out process, a new subsidiary of Blackhawk (“SpinCo”) will be created, which will hold all of the above-named subsidiaries. SpinCo is to be renamed MindBio Therapeutics Corp.

MindBio Therapeutics Corp. will be an independent public company focused on the psychedelic sector and mental health therapies. All shareholders of Blackhawk will receive one common share in MindBio Therapeutics Corp. for every share held in Blackhawk, on a pro rata basis, based on a record date that is expected to be set in early 2022.

Shareholders must hold Blackhawk shares at the record date to qualify to receive shares of MindBio Therapeutics Corp. in the distribution. This transaction will help to unlock the substantial value of the existing investments made by Blackhawk in the psychedelics sector and will allow the business to be operated independently.

The spinout transaction is expected to complete during the second quarter of 2022 and will be subject to approvals from Blackhawk shareholders and the Canadian Securities Exchange (“CSE”).

MindBio Therapeutics Corp. will be a leading multidisciplinary company that combines clinical research from a tier one university, technology and digital therapies. It will be fully funded for its clinical trial program for Phase 2 Psychedelic clinical trials for late-stage cancer patients and Phase 1 digital health clinical trials for treating chronic pain. It is also expected to have surplus working capital which it will use towards meeting its listing requirements and may raise further funds on its own to broaden its clinical trial program and expand its psychedelic clinics internationally.

“We believe the spin-out of MindBio and Digital Mind will be very beneficial to shareholders”, said Frederick Pels, CEO of Blackhawk. “The proposed spin-out is an excellent opportunity for shareholders to maximize the value of their Blackhawk holdings. The goal of this transaction is to unlock further value of the assets by allowing it to be developed separately, in a sector focussed public company by a skilled and experienced management team. It is important to note that to become a shareholder of MindBio, investors will have to be a shareholder of Blackhawk as of the record date. I look forward to updating our shareholders as the progress of the spin-out develops.”

Colin Keating, CEO of MindBio, said: “Combining our team with leading assets in clinical trials and digital therapies, MindBio is positioned to be a leader in the area of medical psychedelics and mental therapies. The spin-out and listing of MindBio on the CSE will allow the company to accelerate expansion activities and bring new products and solutions to market for treating a variety of mental health conditions. In light of the higher company valuations of our peer group in the United States, our goal is to create more shareholder value by bringing this company to the public markets and exposing it to a much broader audience.”

Upon completion of the proposed spinout transaction, Blackhawk will continue to hold 100% interests in TERP Wholesale LLC, Trip Pharma Inc., Sac Pharma Partners Inc., NuWave Foods, Spaced Foods and Noble Hemp Line as well as an equity stake in Gaia Grow (CSE:GAIA) and a 51% interest in LeichtMind.

Proposed Management and Board of Directors of MindBio Therapeutics Corp.

It is anticipated that the board of directors and management of MindBio Therapeutics Corp. will include:

Gavin Upiter – Chairman

Mr. Upiter has over 25 years of experience leading companies in the pharmaceutical sector. Engineering qualified, prior to founding Generic Health, a leading generic pharmaceutical company that was sold to Lupin Pharmaceuticals, Mr. Upiter started his executive career at Bristol Myers Squibb. He was Australian chief executive officer of Amneal Pharmaceuticals and executive director of Slade Health, Australia’s leading hospital pharmacy chain. Mr. Upiter founded Directo, Australia’s first on-line pharmaceutical B2B (business-to-business) marketplace for pharmacies and suppliers.

Dr. Zena Burgess, PhD, FAICD,FAPS – Director

Dr. Burgess has a strong interest in the future of health care. She serves as the chief executive officer of the Australian Psychologists Society and formerly served as chief executive of the Royal Australian College of General Practitioners. She is a member of the international advisory board of Connext2MyDoctor and the telehealth influencers alliance. She is also a director of the Australian Patients Association and chair of the board subcommittee on governance and risk of the Victorian Farmers Federation. Dr. Burgess has substantial experience serving on boards of government entities. She holds a PhD in psychology from the Australian Catholic University and a Master of Business Administration from Monash University and a master of education from La Trobe University. She has a wealth of experience in health changes and strategic advocacy to governments.

Justin Hanka – Director

Mr. Hanka is in investment banking and financing of mergers and acquisitions and capital markets transactions. He is non-executive director of EonX, a financial technology company, non-executive director of Goldcar (a Europcar company listed on the Euronext in France), non-executive director of the Digital Tribes Company, an IT (information technology) digital transformation company headquartered in Sweden.

He is an experienced executive, having served as chief operating officer for iSelect and having sold Helpmechoose as its chief executive officer to Mortgage Choice. Mr. Hanka’s expertise spans the pharmaceutical and health sectors, including pharmaceuticals, pharma technologies, fintechs, digital transformation and technology, influencer marketing, health and wellness, entertainment, and e-commerce.

Colin Keating – Chief Executive Officer

Mr. Keating is an experienced chief executive officer and managing director, having led publicly listed Hogg Robinson Group Australia (London Stock Exchange) and BuyMyPlace (Australian Securities Exchange), both large, private, technology-led organizations, and has also held senior global leadership positions with the likes of American Express. With over 25 years experience in both established and scale-up businesses, Mr. Keating possesses a demonstrable record in driving growth, shaping organizational culture and delivering shareholder value.

His experience is broad and varied, having worked across multiple industries, including financial services and payments, corporate travel, property tech, health tech, data management and wealth management. Mr. Keating also has deep experience working in and advising organizations on strategic initiatives such as capital raising, merger and acquisition activities, initial public offerings, and exit strategies. Having worked in the United Kingdom, Hong Kong and the United States, Mr. Keating’s global experience will be of enormous benefit to MindBio Therapeutics as the business grows both domestically and across international markets.

About MindBio Therapeutics Pty Ltd. (“MindBio”)

MindBio is a clinical-stage drug development company that is pioneering psychedelic microdosing research and is advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD (posttraumatic stress disorder).

In a world’s first clinical trial of its kind, MindBio is currently conducting Phase 1 clinical trials, that is over 50% complete, at a tier 1 university in a safety study of 80 participants microdosing LSD to patients. The study has received regulatory approval and government funding for the importing of LSD, laboratory work using the drug and approvals for participants to be prescribed the drug; and then patients take the drug at home as they would any other medication. Approvals have also been received for two phase 2 clinical trials involving microdosing LSD in late-stage cancer patients experiencing end-of-life distress.

MindBio is also pioneering the development of microdose formulations and a range of technology and artificial intelligence applications to ensure the safe dosage, use and administration of psychedelic medicines in the community. Early indications show that LSD is tolerated well in microdoses and has a lower side effect profile than the currently prescribed antidepressant drugs. MindBio has a detailed roadmap to conduct further clinical trials, including with other psychedelic substances, and a clear plan to bring newly created intellectual property to market and commercialization.

About Digital Mind Technology Pty Ltd. (“Digital Mind”)

Digital Mind is a clinical trial stage company developing digital interventions to treat mental health conditions. It successfully completed a pilot randomized controlled trial with 69 patients of an on-line mindfulness-based program for people diagnosed with melanoma. Digital Mind’s clinical trial protocol was developed by leading scientist Dr. Russell at a major Australian university.

Dr. Russell joined the psycho-oncology research team at the Peter MacCallum Cancer Centre in Melbourne, Australia, evaluating supportive care interventions for people affected by cancer. In 2018, Dr. Russell was awarded her PhD from Deakin University, Australia. Coupling with her personal interest in mindfulness practices and her professional experience in psycho-oncology, Dr. Russell’s PhD research was designed to determine whether a mindfulness program could benefit people with melanoma.

The focus of the program was to empower participants to manage their health by promoting awareness of emotions and teaching skills to manage distressing thoughts. Central to the success of the program was the flexibility offered to participants to access the information at their own convenience. Dr. Russell is dedicated to expand from this early research to build an evidence base informing the development of self-guided interventions promoting the mental health of people affected by cancer and other chronic conditions.

Digital Mind has both the intellectual property, with over five years of quality research intellectual property and the capital to finance its operations. The company will conduct phase 1 clinical trials of mindfulness-based digital programs for people requiring pain management to avoid or reduce the impact on mental health. The clinical trials will be fully compliant with the U.S. Food and Drug Administration’s (FDA) protocol.

Digital Mind is also working to develop digital platforms (mobile, smart watch and Web) that provides clinically proven mindfulness-based digital programs to help patients to deal with pain. These clinical programs have the potential to be provided to patients via health professionals in a clinical setting.

Digital intervention technologies are one of the fastest growth areas in the treatment and prevention of mental health conditions. Financing for technology companies that are developing applications to treat behavioural, mental and brain health exceeded $5.3-billion (U.S.) to Q3 in 2021.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the proposed spinout transaction and future operations of Digital Mind Technology Pty Ltd. and MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth Fully Funds Phase II Clinical Trials in Psychedelics and Begins Development of Digital Mental Health Treatments

Blackhawk Growth Fully Funds Phase II Clinical Trials in Psychedelics and Begins Development of Digital Mental Health Treatments

Vancouver, British Columbia – TheNewswire – December 13, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (“Blackhawk”), is pleased to provide an update on its clinical trials for both of its wholly-owned subsidiaries MindBio Therapeutics PTY Ltd. (“MindBio”) and Digital Mind Technology PTY Ltd. (“Digital Mind”).

MindBio Clinical Trial Update

MindBio is accelerating its clinical trial program and is now fully funded for its Phase II clinical trial for microdosing of psychedelics in late-stage cancer patients. MindBio will be one of only a handful companies that is progressing to a Phase II clinical trial in the psychedelics sector.

The now fully funded Phase II clinical trial will examine the effects of Psychedelic Microdosing Assisted Meaning Centred Psychotherapy (PMA-MCP) in advanced stage cancer patients.

The ground-breaking Phase II trial will examine the feasibility, acceptability and safety of a randomised, double-blind, placebo-controlled trial comparing Psychedelic Microdosing Assisted Meaning Centred Psychotherapy (PMA-MCP) to placebo in advanced stage cancer patients. This trial will help to evaluate whether PMA-MCP provides benefits in advanced stage cancer patients in regard to quality of life, their spiritual well-being, anxiety, depression, hopelessness, and attitudes towards death.

At each quarterly reporting, the intellectual property protection will be discussed and managed between the University of Auckland and MindBio. A qualified medical officer, psychotherapists, and a study nurse will also be appointed for patient therapy and safety.

In addition, MindBio also has the necessary funding to start the development of a second Phase II microdosing depression trial. This will involve the analysis of Phase I trial data, expected to be completed in Q1 2022, which will inform the trial design for Phase II trials for the development of investigator materials and the development of trial protocol documentation.

A pharmacogenomic (liver enzyme genotyping) and pharmacokinetic analyses will also be conducted to help understand the individual variability of response to LSD observed in Phase I study data (see Vizeli et al 2021 Scientific Reports). Furthermore, biomarker analysis will be used to determine potential candidate biomarkers for Phase 2 trials (e.g. mRNA).

MindBio has budgeted to start scientific research to objectively determine the effectiveness of psychedelic microdosing on individuals. This includes developing a platform to ensure time critical requirements of microdosing, personalised algorithms used for optimising microdosing to suit a given individual, artificial intelligent toos for data analytics for studying the impact of therapy on the patient’s mood state, and more.

Digital Mind Technology

Digital Mind has successfully completed a pilot randomized controlled trial with 69 patients of an online mindfulness-based program for people diagnosed with melanoma1. Led by leading scientist Dr. Lahiru Russell, Digital Mind is launching a fully funded Phase I clinical trial of mindfulness-based digital programs for people requiring pain management to avoid or reduce the impact on mental health. The clinical trials will start in Q1, 2022 and will be fully compliant with the Food and Drug Administration’s (FDA) protocols.

Results of Digital Mind’s completed pilot randomized controlled trial showed that psycho-educational interventions can decrease anxiety and health-related distress, and prompt positive change in coping with illness. Improving awareness of thoughts may be a therapeutic approach to reduce worrisome and unhelpful thoughts, which underlie fear of disease that can lead to depression and other mental health problems.

This awareness is an essential component of mindfulness-based interventions in which one is aware of any thoughts, feelings, bodily sensations and surrounding environment occurring moment-by-moment. In this state of awareness, thoughts and feelings are experienced as passing events in the mind, instead of a reflection of oneself or reality. This detached self-observation allows individuals to reflect on situations and respond in more adaptive ways, instead of reacting in an automatic, habitual pattern.

Online and digital based interventions are more easily accessible, available at any time to people in their own environment, enable people to work at their own pace and have the option to remain anonymous. Digital Mind’s Phase I clinical trial will build on the results of the pilot trial and protocols to help develop digital platforms (mobile, smart watch, and web) that provides clinically proven mindfulness-based digital programs to help patients deal with pain that ultimately reduces the impact on their mental health conditions. These clinical programs have the potential to be provided to patients via health professionals in a clinical setting.

“MindBio has taken a significant leap forward”, said Frederick Pels, CEO of Blackhawk Growth. “A fully funded Phase II clinical trial puts the research and progress of MindBio in the top echelon of the booming psychedelic sector. Combined with the addition of Digital Mind and its fully funded Phase I clinical trial, it truly displays the strength and growth of our Company’s psychedelic and life science portfolio. I look forward to updating shareholders as these initiatives progress and as we work hard to unlock substantial value for our shareholders.”  

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

  1. https://www.researchgate.net/publication/329333517_A_pilot_randomised_controlled_trial_of_an_online_mindfulness-based_program_for_people_diagnosed_with_melanoma 

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to future operations of Digital Mind Technology Pty Ltd. and MindBio Therapeutics Pyy Ltd The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth to Complete Strategic Investment of Digital Mind Technology; Fully Funds Phase 1 Clinical Trial for Digital Mind and Phase 2 Clinical Trial for MindBio Therapeutics

Blackhawk Growth to Complete Strategic Investment of Digital Mind Technology; Fully Funds Phase 1 Clinical Trial for Digital Mind and Phase 2 Clinical Trial for MindBio Therapeutics

Highlights:

  • Complementary acquisition of digital wellness company with AUD$2.5M cash on hand 
  • Digital Mind Technology has a fully funded Phase 1 Clinical Trial ongoing 
  • Adds several new high profile and leading institutional psychedelic funds as Blackhawk shareholders 
  • MindBio Therapeutics fully funded Phase 2 Clinical Trials 
  • Blackhawk holding leading assets in legal psychedelic and mental health therapies 

Vancouver, British Columbia – TheNewswire – December 7, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) ( “Blackhawk”), is pleased to announce that it has entered into a binding share purchase agreement, dated effective December 6, 2021, in which it will acquire 100% of the issued and outstanding share capital of Digital Mind Technology Pty Ltd (“Digital Mind”). In consideration for the acquisition, Blackhawk will issue 8,661,290 common shares to the existing shareholders of Digital Mind.

Blackhawk is also pleased to announce that MindBio Therapeutics is accelerating its clinical trial program and is now fully funded for Phase 2 Clinical Trial for microdosing of psychedelic in late-stage cancer patients. MindBio will be one of a handful of companies that is progressing to a Phase 2 clinical trial in the psychedelics sector.

Digital Mind Technology is an arms-length privately held clinical trial stage company developing digital interventions to treat mental health conditions. It successfully completed a pilot randomized controlled trial with 69 patients of an online mindfulness-based program for people diagnosed with melanoma1. Digital Mind’s clinical trial protocol was developed by leading scientist, Dr Russell, at a major Australian university.

Dr. Russell graduated with a Master in Biochemistry from the University of Geneva, Switzerland. She has worked for a decade in the pharmaceutical industry managing clinical trials. Over the years, Dr. Russell developed an interest in the psychosocial adaptation to illness and strategies to manage stress-related aspects of diseases. Her studies in Epidemiology at the London School of Hygiene and Tropical Medicine (UK) stimulated her desire to undertake research in this field.

Following this, Dr. Russell joined the psycho-oncology research team at the Peter MacCallum Cancer Centre in Melbourne, Australia, evaluating supportive care interventions for people affected by cancer. In 2018, Dr. Russell was awarded her PhD from Deakin University, Australia. Coupling with her personal interest in mindfulness practices and her professional experience in psycho-oncology, Dr. Russell’s PhD research was designed to determine whether a mindfulness program could benefit people with melanoma.

The focus of the program was to empower participants to manage their health by promoting awareness of emotions and teaching skills to manage distressing thoughts. Central to the success of the program was the flexibility offered to participants to access the information at their own convenience. Dr Russell is dedicated to expand from this early research to build an evidence base informing the development of self-guided interventions promoting the mental health of people affected by cancer and other chronic conditions.

Digital Mind has both the intellectual property, with over 5 years of quality research intellectual property and the capital, with approximately AUD$2.5million in working capital to fund its operations. Digital Mind will conduct Phase 1 clinical trials of mindfulness-based digital programs for people requiring pain management to avoid or reduce the impact on mental health. The clinical trials will be fully compliant with the Food and Drug Administration’s (FDA) protocol.

Digital Mind is also working to develop digital platforms (Mobile, Smart Watch, and Web) that provides clinically proven mindfulness-based digital programs to help patients to deal with pain. These clinical programs have the potential to be provided to patients via health professionals in a clinical setting.

Digital intervention technologies are one of the fastest growth areas in the treatment and prevention of mental health conditions. Funding for technology companies that are developing applications to treat behavioural, mental and brain health exceeded
US$5.3 billion to Q3 in 20212.

“The acquisition of Digital Mind will help scale our life science and psychedelic portfolio tremendously” said Frederick Pels, CEO of Blackhawk Growth. “It will allow our psychedelic microdosing company, MindBio Therapeutics, to have close collaboration ties with Digital Mind for both product development and commercialization activities. A robust digital mental health platform will form the 3rd pillar of our multi-disciplinary mental health solution combining with our existing tier 1 university grade clinical research and established mental health clinics. We look forward to updating our shareholders with our progress over the coming weeks and months as well as details of our clinical trials shortly.”

Dr. Zena Burgess has also been appointed to Digital Mind advisory board. Dr. Burgess serves as Director of MindBio Therapeutics and is also a member of the international advisory board of Connext2MyDoctor and the telehealth influencers alliance. Dr. Burgess is currently the Chief Executive Officer of the Australian Psychologists Society. Formerly, Dr. Burgess was Chief Executive of the Royal Australian College of General Practitioners. Dr. Burgess has substantial experience serving on boards of government entities.

She holds a PhD in psychology and a Master of Business Administration and a Master of Education. She has a wealth of experience in health changes and strategic advocacy to governments.

Digital Mind also has several high-profile shareholders including some of the largest psychedelic funds who will now become shareholders of Blackhawk through this acquisition. They include for instance:

Iter Investments
Iter Investments is a venture capital firm based in the USA focused on supporting emerging companies within the psychedelic ecosystem of behavioral and mental health.

https://www.iterinvestments.com/

The Conscious Fund 
The Conscious Fund is an early-stage venture capital firm headquartered in London, United Kingdom. The firm seeks to invest in psychedelics medicine.

HOME

Transaction Structure

In connection with the acquisition, Blackhawk will acquire all of the outstanding share capital of Digital Mind Technology Pty Ltd. in consideration for the completion of the transaction, Blackhawk is required to issue 8,661,290 common shares to the existing shareholders of Digital Mind. One-half of these shares will be subject to restrictions on resale for a period of four months and one day following issuance. No finders’ fees or commissions are payable by Blackhawk in connection with the acquisition.

Blackhawk is at arm’s length from Digital Mind and its shareholders. The transaction neither constitutes a fundamental change nor a change of business for Blackhawk, nor is it expected to result in a change of control of Blackhawk within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Completion of the acquisition remains subject to the satisfaction of customary closing conditions. Following completion of the acquisition, Digital Mind will expand Blackhawk’s existing portfolio of investments in the health care sector.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Publications By Dr Russell

  • Russell, L., Whiffen, R., Chapman, L., Just, J., Dean, E., Ugalde, A. and White, S., 2021. Hospital staff perspectives on the provision of smoking cessation care: a qualitative description study. BMJ open, 11(5), p.e044489. DOI: 10.1136/bmjopen-2020-044489 
  • Lynch, F.A.; Katona, L.; Jefford, M.; Smith, A.B.; Shaw, J.; Dhillon, H.M.; Ellen, S.; Phipps-Nelson, J.; Lai-Kwon, J.; Milne, D.; Russell, L.; Dax, V.; Diggens, J.; Kent, H.; Button-Sloan, A.; Elliott, J.; Shackleton, M.; Burridge, H.; Ftanou, M. Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma. J. Clin. Med. 2020, 9, 2969. DOI: 10.3390/jcm9092969 
  • Russell, L., McIntosh, R., Martin, C., Scott J., Kheng Soo W., Zappa B., Haynes K., Livingston PM. Ugalde, A. A model of cancer survivorship care within a community health setting: the Good Life Cancer Survivorship program. Journal of Cancer Survivorship. 2019 DOI: 10.1007/s11764-019-00821-6 
  • Russell, L., Ugalde, A., White, V., Pitcher, M., Jorgensen, S., Whitfield, K., … Livingston, P. Relevance of mindfulness practices for Culturally And Linguistically Diverse cancer populations. PsychoOncology, 2019 DOI: 10.1002/pon.5221 
  • Ugalde A, Haynes K, White V, Russell L, Livingston PM. “An Ambition to Make People Feel at Home” or “The Emperor’s New Clothes”? Professional Stakeholder Views of Wellness Centres in Cancer Care. European Journal of Cancer Care. 2019 DOI: 10.1111/ecc.13096 
  • Russell L, Pascoe MC, Seymour JF, Aranda S, Butow P, Gough K, Schofield P. The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials. BMC research notes. 2019 Dec;12(1):226. 
  • Russell L, Ugalde A, Orellana L, Milne D, Krishnasamy M, Chambers C, Austin D and Livingston P M, A pilot randomised controlled trial of an online mindfulness-based program for people diagnosed with melanoma, Journal of Supportive Care in Cancer. 2018 DOI: 10.1007/s00520-018-4574-6  
  • Russell L, Ugalde A, Milne D, Austin D and Livingston P M, Digital Characteristics and Dissemination Indicators to Optimize Delivery of Internet-Supported Mindfulness-Based Interventions for People With a Chronic Condition: Systematic Review, JMIR Mental Health. 2018 DOI: 10.2196/mental.9645  
  • Russell L, Ugalde A, Milne D, Krishnasamy M, Chung Seul O E, Austin D, Chambers R, Orellana L, and Livingston PM, Feasibility of an online mindfulness-based program for patients with melanoma: study protocol for a randomised controlled trial, Trials. 2018 Dec; 19(1):223 
  • Pereira-Salgado A, Westwood JA, Russell L, Ugalde A, Ortlepp B, Seymour JF, Butow P, Cavedon L, Ong K, Aranda S, Breen S.,… Schofield P, Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment, JMIR mHealth and uHealth. 2017. DOI: 10.2196/mhealth.8349 
  • Russell L, Orellana L, Ugalde A, Milne D, Krishnasamy M, Chambers R, Livingston PM., Exploring Knowledge, Attitudes, and Practice Associated With Meditation Among Patients With Melanoma, Integrative Cancer Therapies, 2017. DOI: 10.1177/1534735417699514 
  • Jefford M, Gough K, Drosdowsky A, Russell L, Aranda S, Butow P, Phipps-Nelson J, Young J, Krishnasamy M, Ugalde A, King D., … and Schofield P, A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer, Oncologist, 2016. DOI: 10.1634/theoncologist.2015-0533 
  • Russell L, Gough K, Drosdowsky A, Schofield P, Aranda S, Butow PN, Westwood JA, Krishnasamy M, Young JM, Phipps-Nelson J, King D. Jefford M, , Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment, Journal of Cancer Survivorship, 2015. DOI: 10.1007/s11764-014-0422-y  
  • Jefford M, Mann GB, Nolte L, Russell L, Brennan M., Follow-up of Women with Early Stage Breast Cancer. Current Breast Cancer Reports, 2014. DOI:10.1007/s12609-014-0150-3 
  • Jefford M, Aranda S, Gough K, Lotfi-Jam K, Butow P, Krishnasamy M, Young J, Phipps-Nelson J, Russell L, King D, Schofield P., Evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial, Trials 2013. DOI: 10.1186/1745-6215-14-260 

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of Digital Mind Technology Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth’s MindBio Therapeutics Advances Microdosing Clinical Trial to 59 Patients

Blackhawk Growth’s MindBio Therapeutics Advances Microdosing Clinical Trial to 59 Patients

Vancouver, British Columbia – TheNewswire – November 15, 2021 – Blackhawk Growth Corp. (CNSX:BLR) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that their wholly-owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), has reached a new milestone for its Phase 1 clinical trial microdosing LSD with 59 participants successfully completing the trial.  The clinical trial is the first and largest safety clinical trial of its kind anywhere in the world.

MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.

MindBio is on track to have its Phase 1 clinical trial in 80 healthy participants completed by April in 2022.  In this unique study, trial participants are prescribed the drug by a doctor and take it home with them in the same way they would take an anti-depressant medication.  Clinical trial participants are assessed on a comprehensive range of psychometric and biometric markers to determine safety and efficacy of the drug.

LSD is a psychoplastogen, which is a fast-acting class of therapeutics, capable of rapidly promoting structural and functional neural plasticity and shows potential for treating diseases in psychiatry1. Microdosing involves patients taking a small amount of the medicine on a regular basis.  In larger doses, LSD is a hallucinogenic drug that changes cognition and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.

“This is extremely exciting work” says Frederick Pels, CEO of Blackhawk Growth Corp. “Our clinical trial is paving the way forward to create a class of new medicines that propose novel and effective solutions for treating serious mental illness. MindBio continues to demonstrate how its exceptional team of clinicians and engineers are dedicated to building products that can have a significant impact on people’s lives. I look forward to updating shareholders as developments continue to progress.”

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149016/

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.